NasdaqGS:BMRNBiotechs
A Look At BioMarin Pharmaceutical (BMRN) Valuation After A Year Of Softer Share Price Momentum
BioMarin Pharmaceutical (BMRN) is back on investor watch after recent trading left the shares about 20% lower over the past year, despite annual revenue of US$3.2b and net income of US$348.9m.
See our latest analysis for BioMarin Pharmaceutical.
The recent 1 day share price return of 1.85% decline and 7 day share price return of 5.67% decline sit against a 90 day share price return of 10.93% and a 1 year total shareholder return of 19.73% decline, suggesting short term momentum has softened...